Premium
Expression of Bcl‐2 but not Bax has a prognostic significance in tongue carcinoma
Author(s) -
Vicente Juan Carlos,
Olay Sonsoles,
LequericaFernandez Paloma,
SánchezMayoral Jacobo,
Junquera Luis Manuel,
Fresno Manuel Florentino
Publication year - 2006
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2006.00378.x
Subject(s) - immunohistochemistry , pathology , apoptosis , epidermoid carcinoma , carcinogenesis , tongue , bcl 2 associated x protein , biology , carcinoma , grading (engineering) , cancer , programmed cell death , pathogenesis , cancer research , medicine , caspase 3 , ecology , biochemistry
Background: Among the molecular mechanisms involved in carcinogenesis, defects in the regulation of programmed cell death (apoptosis) make important contributions to the pathogenesis and progression of cancer. Apoptosis regulatory genes include the antiapoptotic bcl‐2 gene and the proapoptotic bax gene. The aim of this study was to determine the spectrum of Bax and Bcl‐2 expression, and to correlate these findings with clinicopathologic variables and prognosis. Methods: In this study we have evaluated the immunohistochemical expression of Bcl‐2 and Bax proteins in a series of 35 squamous cell carcinomas of the tongue. Results: Immunoreactivity for Bax was detected in 37.1% and for Bcl‐2 in 8.6% of cells, and for both proteins the staining was cytoplasmic and granular. Bcl‐2 and Bax expression was mainly seen in peripheral cells of epithelial tumor islands with decreasing immunoreactivity toward the center of the neoplastic nests. Bax immunoexpression was significantly correlated with histologic grading ( P = 0.05), but not with the remaining clinicopathologic variables. Bcl‐2 immunoreactivity was significantly correlated with N‐stage ( P = 0.01) and survival. Patients with Bcl‐2‐negative tumors [mean survival: 73.97 months; 95% confidence interval (CI): 59–88] vs. Bcl‐2‐positive ones (mean survival: 17.67 months; 95% CI: 6–29) had a longer survival ( P = 0.01; odds ratio = 6.9). Conclusions: Bcl‐2 is associated with aggressive disease, neck lymph node metastasis, and poor prognosis. Whereas Bax is related with histologic grade.